Thrasos Therapeutics

Thrasos Therapeutics, founded in 2003, was a clinical-stage biotherapeutics company headquartered in Montreal, Canada, with a satellite office in Boston, Massachusetts. The company focused on developing new treatments for kidney diseases, an area with significant unmet medical needs. Thrasos' operations were supported by substantial venture capital, raising a total of $64 million over several funding rounds. Notable financing includes a $35 million Series C round in 2012, led by SR One, the venture capital arm of GlaxoSmithKline. This was followed by a $21 million Series D round in 2015, co-led by BDC Capital and SR One, to fund a large-scale Phase 2 clinical trial.

The company's primary business was the discovery and development of peptide-based drug candidates designed to protect, repair, and restore kidney function. The business model was centered on advancing these candidates through clinical trials to demonstrate safety and efficacy, with the ultimate goal of commercialization. The target market included patients at risk for or suffering from Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD). AKI, in particular, presented a considerable market opportunity as there were no approved drug therapies for the condition.

Thrasos' lead product candidate was THR-184, a small peptide mimetic of the naturally occurring protein BMP-7. This compound was developed to prevent AKI, especially in high-risk patients undergoing cardiac surgery. THR-184 worked by selectively activating specific cellular pathways that inhibit inflammation, apoptosis (cell death), and fibrosis (scarring). A key benefit of THR-184 was its targeted mechanism, which aimed to offer the therapeutic advantages of the BMP-7 pathway without the associated deleterious effects. The company advanced THR-184 into a 450-patient Phase 2 clinical study, which completed enrollment in 2015. Despite promising preclinical data and successful completion of the Phase 2 trial, PitchBook data indicates the company is now out of business.

Keywords: kidney disease, biotherapeutics, Acute Kidney Injury, Chronic Kidney Disease, clinical trials, peptide compounds, renal failure, drug discovery, THR-184, diabetic nephropathy, SR One, BDC Capital, GlaxoSmithKline, peptide mimetic, BMP-7 agonist, nephrology, renal therapeutics, clinical-stage pharma, organ protection, fibrosis treatment, apoptosis inhibitor, inflammation modulation